US FDA Expediting ANDA Postapproval Manufacturing Changes Due To COVID-19 Impacts

 
• By Sue Sutter
  
To do list conceptual
Nonindustry stakeholders shared their GDUFA III 'to do' list with FDA and generic drug companies. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics